VNDA - NASDAQ

Ladies and gentlemen, thank you for standing by. And welcome to the Quarter 1 2022 Vanda Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would like to turn the call over to our speaker today, Kevin Moran, Vanda's Chief Financial Officer. Sir, you may begin.

Thank you, .Good afternoon. And thank you for joining us to discuss Vanda Pharmaceuticals First Quarter 2022 performance. Our first-quarter 2022 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board. Additionally, we have Timothy Williams, our General Counsel, and Gunther Beers next, our Senior Vice President of Business Development and R&D Committee Member. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before opening the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of Federal Securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, change in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and Management's discussion and analysis of financial condition, and results of operations, sections of our annual report on Form 10-K for the fiscal year ended December 31st, 2021, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC, which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today, and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mihael Polymeropoulos.

Thank you very much Kevin. Good afternoon, everyone. Thank you for joining us today to discuss Vanda's first quarter 2022 results. We believe 2022 is going to be an exciting year for the company, as we strengthen our commercial efforts and advance our clinical pipeline. Turning first to commercial performance. On HETLIO

Thank you, Mihael. I'll begin by summarizing our first quarter 2022 financial results. Total revenues for the first quarter of 2022 were $60.2 million, a 4% decrease compared to $62.7 million for the first quarter of 2021. HETLIO

Thank you very much Kevin. At this point we will be happy to answer any questions you may have.

Thank you very much. And thank you for joining us. We'll talk to you in the near future. Thank you.